Navigation Links
Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
Date:8/6/2013

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report second quarter 2013 operational results after closing of the NASDAQ Global Market on August 13, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update at 5 p.m. EDT (2 p.m. PDT), August 13, 2013.

The call will be webcast live and may be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify to the operator that you would like to join the "Ambit Second Quarter 2013 Operating Results Call, conference ID 35424048."  A teleconference replay will be available through Monday, August 19, 2013.  Interested parties can access the replay by dialing 888-843-7419, or 630-652-3042 internationally, and entering the conference number 35424048.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit Biosciences website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Friday, September 13, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
2. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
3. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
6. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
9. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
10. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
11. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... Mich., Feb. 1, 2011 Fiscal second quarter ... million Fiscal second quarter GAAP income from continuing ... per share Fiscal second quarter adjusted income from ... Record second quarter cash flow from operations of ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ), ... for therapeutic applications, infection control, and water purification, today ... its previously announced rights offering to its existing stockholders ... Securities and Exchange Commission. Under the terms ...
Cached Medicine Technology:Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 2Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 3Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 4Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 5Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 6Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 7Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 8Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 9Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 10Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 11Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 12Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 13Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 14Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 15Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 16Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 17Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 18Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
(Date:7/31/2014)... July 31, 2014 Joseph M. Lee, ... Hudson Valley (CDHV), a leading provider of quality cardiovascular ... Hudson Valley. Dr. Lee is a board certified ... , In addition to his position at CDHV, ... New York-Presbyterian Hospital/ Columbia University Medical Center. Dr. Lee ...
(Date:7/31/2014)... Bedford Commons OB-GYN partnered with local growth ... to do what Christina Haag, the practice administrator referred ... all while still offering the greatest service to our ... health needs for every stage of their life – ... Gynecology ), worked diligently with their marketing and strategy ...
(Date:7/31/2014)... 31, 2014 Transvaginal mesh lawsuits ( ... move forward in the federal multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated July ... defense motions now pending before the Court. The telephonic ... on Tuesday, August 5th at 2:30 p.m. (In re: ...
(Date:7/31/2014)... Live To Be Sober , a no-cost 24/7 ... and program information to people who want to help ... alcohol addiction, proudly announced today that it has entered ... bad boy, gone good. , "NBC's The Voice touched ... whose new single Stomp (#Stomp; available on iTunes ...
(Date:7/31/2014)... London, UK (PRWEB) July 31, 2014 ... in the development and maintenance of products in the ... can be performed by using various products and equipment ... and spoilage of various materials and products. , ... and services is forecast to post a CAGR of ...
Breaking Medicine News(10 mins):Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 2Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 4Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 3Health News:Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good 2Health News:Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3
... Inc. today will present Phase II clinical data ... next-generation antidepressant, is effective for treating major depressive ... outcome for depression. EB-1010 also improved measures of ... characterized by the inability to experience pleasure. The ...
... , TUESDAY, Dec. 7 (HealthDay News) -- Electronic cigarettes ... University of California researchers say. Their study ... devices that contain nicotine, flavorings and other chemicals. The ... and Drug Administration cited five e-cigarette distributors for poor ...
... pioneering clinical trial is testing the effectiveness in leukemia of ... can disable the well-known tumor suppressor p53. Michael ... Hematology and Therapy in the Department of Leukemia at The ... of this ongoing Phase I study at the 52nd Annual ...
... Madonna Behen HealthDay Reporter , TUESDAY, Dec. ... who suffer concussions may have different symptoms than boys, ... boys are more likely to report amnesia and confusion/disorientation, ... to noise more often. "The take-home message is ...
... A school-based intervention program designed for adolescents with ... life for the students who participate, and reduces ... City, who studied the effect of the program ... The Asthma Self-Management for Adolescents (ASMA) program is ...
... HealthDay Reporter , TUESDAY, Dec. 7 (HealthDay News) -- ... folks because they create a network of close friends ... Conducted at the University of Wisconsin, the researchers found ... say they are "extremely satisfied" with life as opposed ...
Cached Medicine News:Health News:Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting 2Health News:Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting 3Health News:E-Cigarettes Should Be Banned Until Made Safe: Study 2Health News:Small molecule may disarm enemy of cancer-fighting p53 2Health News:Concussion Symptoms Can Differ for Boys and Girls 2Health News:Concussion Symptoms Can Differ for Boys and Girls 3Health News:School-based program helps adolescents cope with asthma 2Health News:School-based program helps adolescents cope with asthma 3Health News:Friends May Be Key to Churchgoers' Happiness 2Health News:Friends May Be Key to Churchgoers' Happiness 3
... Premier Anterior Cervical Plate System allows ... translation along slots in the plate, ... distal end of the construct. In ... graft pre-compression features that enable the ...
... Cervive is an Anterior Cervical Plating ... provide flexibility and simplicity for the ... anatomical function and safe fixation of ... that meet the needs of the ...
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
The Codman anterior cervical plate is designed for immediate internal fixation of the cervical spine following bone grafting procedures....
Medicine Products: